GTHX — G1 Therapeutics Share News
0.000.00%
Last trade - 00:00- $377.22m
- $360.81m
- $82.51m
G1 Therapeutics dives as Q3 cancer drug sales miss estimates
G1 Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Initial Results From Phase 2 Trial Demonstrate Potential Of Trilaciclib
Brief: G1 Therapeutics Provides Third Quarter 2022 Financial Results And Operational Highlights
G1 Therapeutics Inc expected to post a loss of 63 cents a share - Earnings Preview
Brief: G1 Therapeutics Announces Investigator Initiated Study Of Trilaciclib And Lurbinectedin
Brief: G1 Therapeutics Completes Enrollment In Phase 3 Clinical Trial Of Trilaciclib
Wedbush sees strong growth potential for G1 Therapeutics' drug, hikes PT
Brief: G1 Therapeutics Reports Q2 Loss Per Share $0.92
Brief: G1 Therapeutics Announces Addition Of Norman E. Sharpless To Board
Brief: G1 Therapeutics Completes Enrollment In Global Multi-Center Phase 3 Clinical Trial Of Trilaciclib In Patients With Metastatic Colorectal Cancer
Brief: Data Presented At Asco Demonstrate Trilaciclib Helps Protect Against Severe Neutropenia, Severe Anemia, And Severe Thrombocytopenia When Given To Extensive-Stage Small Cell Lung Cancer (Es-Sclc) Patients Prior To Chemotherapy
G1 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: G1 Therapeutics Provides First Quarter 2022 Financial Results
G1 Therapeutics Inc expected to post a loss of 97 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-GameStop Corp, Blackberry Ltd, Sage Therapeutics
G1 Therapeutics rises on bone marrow treatment data
Brief: New Real-World Data Show Potential Of Trilaciclib To Reduce The Substantial Burden Of Myelosuppression In Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Chemotherapy
U.S. RESEARCH ROUNDUP-Avanos Medical, Kraft Heinz, NetApp